Get the Stockscreener App
23.12
0.99%
-0.23
Pharvaris Nv stock is traded at $23.12, with a volume of 53,502.
It is down -0.99% in the last 24 hours and up +0.00% over the past month.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
See More
Previous Close:
$23.35
Open:
$23.67
24h Volume:
53,502
Relative Volume:
0.57
Market Cap:
$1.42B
Revenue:
-
Net Income/Loss:
$-143.59M
P/E Ratio:
-8.1881
EPS:
-2.8236
Net Cash Flow:
$-119.47M
1W Performance:
+3.68%
1M Performance:
+0.00%
6M Performance:
+40.21%
1Y Performance:
+26.96%
1-Day Range:
$22.86
$23.77
1-Week Range:
$21.56
$24.01
52-Week Range:
$11.51
$26.33
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
23.12 | 1.42B | 0 | -143.59M | -119.47M | -2.8236 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Initiated | Guggenheim | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-25-23 | Initiated | Wedbush | Outperform |
| Aug-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-05-22 | Initiated | Bryan Garnier | Buy |
| Sep-13-22 | Resumed | JMP Securities | Mkt Outperform |
| Aug-23-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-22-22 | Downgrade | BofA Securities | Neutral → Underperform |
| May-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Mar-02-21 | Initiated | BofA Securities | Neutral |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | Oppenheimer | Outperform |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
View All
Pharvaris Nv Stock (PHVS) Latest News
How institutional ownership impacts Pharvaris N.V. stockIPO Watch & Reliable Entry Point Alerts - Newser
Is Pharvaris N.V. stock bottoming out2025 Risk Factors & High Win Rate Trade Alerts - Newser
What Fibonacci levels say about Pharvaris N.V. reboundPortfolio Value Summary & Consistent Profit Trading Strategies - Newser
Real time pattern detection on Pharvaris N.V. stock2025 Volatility Report & Long-Term Growth Stock Strategies - Newser
Key resistance and support levels for Pharvaris N.V.2025 Major Catalysts & Weekly Chart Analysis and Trade Guides - Newser
Resistance Break Could Fuel Pharvaris N.V. RallyJuly 2025 Opening Moves & Community Verified Trade Signals - mustnews.co.kr
Sector ETF performance correlation with Pharvaris N.V.Portfolio Risk Report & Fast Exit and Entry Trade Guides - Newser
Technical analysis overview for Pharvaris N.V. stockEarnings Overview Report & Stock Market Timing Techniques - Newser
Pharvaris Advances Clinical Pipeline with Strong Financials - TipRanks
Pharvaris N.V. stock momentum explainedWeekly Risk Summary & Safe Entry Momentum Stock Tips - Newser
When is the best time to exit Pharvaris N.V.July 2025 Review & Technical Buy Zone Confirmation - Newser
Pharvaris N.V. stock daily chart insightsMarket Trend Review & Growth Focused Stock Reports - Newser
Relative strength of Pharvaris N.V. in sector analysisBuy Signal & Accurate Entry and Exit Point Alerts - Newser
Smart tools for monitoring Pharvaris N.V.’s price actionGap Up & Free Technical Confirmation Trade Alerts - Newser
Does Pharvaris N.V. qualify in momentum factor screeningJuly 2025 Sentiment & Stock Portfolio Risk Management - Newser
Pharvaris N.V. Nearing Breakout Level After Bounce2025 Earnings Surprises & Daily Market Momentum Tracking - 선데이타임즈
Real time alert setup for Pharvaris N.V. performance2025 Analyst Calls & Capital Protection Trading Alerts - Newser
What is Leerink Partnrs’ Estimate for Pharvaris Q3 Earnings? - Defense World
Using data tools to time your Pharvaris N.V. exitTrade Entry Summary & Low Risk Entry Point Tips - Newser
Understanding Pharvaris N.V.’s price movementQuarterly Trade Report & High Conviction Investment Ideas - Newser
Can Pharvaris N.V. recover in the next quarterShort Setup & Real-Time Chart Breakout Alerts - Newser
Pharvaris N.V. stock outlook for YEARRisk Management & Free Community Consensus Stock Picks - Newser
Cantor Fitzgerald Lifts Earnings Estimates for Pharvaris - Defense World
Is Pharvaris N.V. a Top Dividend Stock to Watch in 2025July 2025 Spike Watch & Daily Oversold Bounce Ideas - Newser
Equities Analysts Issue Forecasts for Pharvaris Q3 Earnings - Defense World
BofA Securities Adjusts Price Target on Pharvaris to $16 From $14, Maintains Underperform Rating - MarketScreener
JMP Securities Issues Pessimistic Forecast for Pharvaris (NASDAQ:PHVS) Stock Price - Defense World
New Product Launches: Will They Boost Pharvaris N.V. Stock in 20252025 Top Gainers & Real-Time Market Trend Scan - Newser
JMP Securities Analyst Lowers PHVS Price Target to $52.00 - AInvest
Pharvaris: JMP Securities maintains Market Outperform, PT down to $52. - AInvest
Pharvaris stock price target lowered to $52 by Citizens JMP - Investing.com Nigeria
Tools to monitor Pharvaris N.V. recovery probabilityWeekly Profit Recap & Smart Allocation Stock Tips - Newser
Using portfolio simulators with Pharvaris N.V. includedDaily Upside Movement Prediction With Data - Newser
Pharvaris Nv Stock (PHVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):